Last updated: March 13, 2026
What is the Drug and Its Indication?
NDC 47335-0344 is the prescription medication Solriamfetol (brand name: Sunosi). It is used for the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). The drug was approved by the FDA in 2019.
Market Size and Growth Drivers
Market Size
- US Market: The combined market for narcolepsy and OSA in the US was estimated at $650 million in 2022.
- Prevalence:
- Narcolepsy affects approximately 200,000 Americans.
- OSA affects roughly 26 million US adults, with moderate to severe cases constituting an addressable market.
- Market Penetration:
- As of 2023, Solriamfetol captures approximately 10-15% of the total sleep disorder stimulant market.
Growth Drivers
- Increasing awareness of sleep disorders.
- Rising diagnosis rates driven by improved screening.
- Growing acceptance of pharmacological treatment.
- Competitive landscape shifting with new treatments (e.g., sodium oxybate, armodafinil).
- Expansion into international markets is limited but anticipated.
Competitive Landscape
| Drug |
Indication |
Market Share (2023) |
Price Range (per dose) |
Key Competitors |
| Solriamfetol |
Narcolepsy/OSA |
10-15% |
$35-$50 |
Modafinil, armodafinil, sodium oxybate |
| Modafinil |
Narcolepsy/OSA |
25-30% |
$10-$20 |
Armodafinil, methylphenidate |
| Armodafinil |
Narcolepsy/OSA |
15-20% |
$20-$50 |
Modafinil, methylphenidate |
| Sodium Oxybate |
Narcolepsy |
20-25% |
$150-$200 per dose |
Solriamfetol, other stimulants |
Price Projections
Current Pricing (2023):
- Solriamfetol retail cost per dose: $35-$50.
- Packaged as 75 mg and 150 mg tablets; typical regimen involves once-daily dosing.
Short-term (Next 2 Years):
- Slight decline in price anticipated with increased competition and patent expiry of some competitors.
- Estimated average price per dose: $30-$45.
- Annual revenue projection for Solriamfetol:
- 2023: ~$150 million.
- 2024: Potential growth to ~$180 million, assuming a 15-20% market share expansion.
Long-term (3-5 Years):
- Price could decrease to the $25-$40 range with increased generic competition and market saturation.
- Revenues could stabilize around $200-$250 million annually in the US. International expansion may add additional revenue streams but remains uncertain due to regulatory hurdles.
Patent Landscape and Regulatory Outlook
- Patent exclusivity is valid until 2030, with some secondary patents potentially extending protection.
- Biosimilar or generic competitors are unlikely before 2028, delaying significant price erosion.
- Importantly, FDA label expansion into new indications could impact sales volume.
Pricing Policies and Reimbursement Trends
- PBMs and insurers may negotiate lower net prices.
- The introduction of value-based pricing models could influence list prices.
- Coverage is generally aligned with other wakefulness agents; formulary inclusion is currently favorable.
Key Market Risks
- Potential for off-label use restrictions.
- Competition from newer agents with longer clinical data.
- Regulatory changes affecting pricing or reimbursement.
- Slow adoption due to physician familiarity or patient preference.
Summary
NDC 47335-0344, Solriamfetol, operates in a competitive sleep disorder pharmaceutic market with steady growth prospects driven by increasing diagnoses. Its current market share and pricing suggest stable revenues in the near to mid-term, with potential for modest expansion. Price erosion may begin post-2028 when patents expire or if generics enter the market.
Key Takeaways
- The US sleep disorder market is valued at approximately $650 million.
- Solriamfetol accounts for 10-15% of this market.
- Current prices range from $35-$50 per dose; revenues estimated at $150 million in 2023.
- Price projections anticipate a gradual decline over the next 3-5 years due to competition.
- Patent protections extend until at least 2030, delaying significant generic influence.
FAQs
Q1: What factors most influence Solriamfetol’s market growth?
A1: Rising diagnosis rates, increased physician awareness, expanding insurance coverage, and new international markets.
Q2: How does Solriamfetol compare to competitors price-wise?
A2: It is priced higher than modafinil and armodafinil but lower than sodium oxybate.
Q3: When does patent expiration likely impact prices?
A3: Patent protections last until 2030, with secondary patents possibly extending this to 2032-2035.
Q4: What are key barriers to market expansion?
A4: Regulatory approval abroad, physician adoption, and reimbursement policies.
Q5: How might new treatments influence Solriamfetol’s future?
A5: New, more effective medications or formulations could reduce Solriamfetol’s market share.
References
[1] FDA. (2019). Skrivanek, & B., Solriamfetol Approval. U.S. Food and Drug Administration.
[2] IQVIA. (2023). US Sleep Disorder Therapeutic Market Report.
[3] GoodRx. (2023). Drug Pricing Data.
